Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Serial Multi-omics Uncovers Anti-Glioblastoma Responses Not Evident by Routine Clinical Analyses (Global Proteomics)

ABSTRACT: Recurrent glioblastoma (rGBM) is incurable. Serial “multi-omic” assays from longitudinal rGBM biopsies may unravel tumor responses to a treatment. Despite traditional imaging indicating tumor progression, 86 serial rGBM biopsies cores obtained over 4 months from the first two patients on a clinical trial of repeated intratumoral doses of the immunotherapeutic agent, CAN-3110, revealed therapeutic effects by multi-omic analyses, including: a-longitudinal and spatial reshaping of the rGBM’s microenvironment, b- expansion of new T cell tissue-resident effector memory clonotypes against newly characterized CAN-3110 epitopes and other undetermined antigens, and c-novel expression of HLA-immunopeptides including cancer testes antigens. The two treated patients achieved a pathologic response or stable clinical disease, respectively. These results show the value of longitudinal tissue sampling to understand GBM’s evolution during an investigational therapy.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Brain

DISEASE(S): Brain Glioblastoma Multiforme

SUBMITTER: Break Through Cancer

LAB HEAD: Forest M.

PROVIDER: PXD063408 | Pride | 2025-10-08

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	Patient1_GP_F.mzData	Other
	Patient1_GP_F1.raw	Raw
	Patient1_GP_F10.raw	Raw
	Patient1_GP_F2.raw	Raw
	Patient1_GP_F3.raw	Raw

Items per page:

1 - 5 of 32

Similar Datasets

Serial Multi-omics Uncovers Anti-Glioblastoma Responses Not Evident by Routine Clinical Analyses (Phosphoproteomics)

Project description:Recurrent glioblastoma (rGBM) is incurable. Serial “multi-omic” assays from longitudinal rGBM biopsies may unravel tumor responses to a treatment. Despite traditional imaging indicating tumor progression, 86 serial rGBM biopsies cores obtained over 4 months from the first two patients on a clinical trial of repeated intratumoral doses of the immunotherapeutic agent, CAN-3110, revealed therapeutic effects by multi-omic analyses, including: a-longitudinal and spatial reshaping of the rGBM’s microenvironment, b- expansion of new T cell tissue-resident effector memory clonotypes against newly characterized CAN-3110 epitopes and other undetermined antigens, and c-novel expression of HLA-immunopeptides including cancer testes antigens. The two treated patients achieved a pathologic response or stable clinical disease, respectively. These results show the value of longitudinal tissue sampling to understand GBM’s evolution during an investigational therapy.

2025-10-08 | PXD063976 | Pride

Serial Multi-omics Uncovers Anti-Glioblastoma Responses Not Evident by Routine Clinical Analyses (Immunopeptidomics)

2025-10-08 | PXD063512 | Pride

ScRNA-seq of human kidney immune cells of patients with ANCA-associated glomerulonephritis, Lupus Nephritis against a healthy nephrectomy control

Project description:ANCA-associated glomerulonephritis (AGN) associates with a high risk of end-stage kidneydisease. The role of kidney immune cells in local inflammation remains unclear. Herewe investigate kidney immune cell diversity and function. Kidney tissue from AGN patients (n=5) and a lupus nephritis (LN) patient (n=1) were aquired during a biopsy procedure for a clinical indication. Needle-core biopsies were obtained for histopathological examination, and an additional pass was performed to retrieve kidney tissue for scRNA-seq. Healthy kidney tissue (n=1) was obtained from a kidney that was surgically removed do tue due to a (non-invasive) papillary urothelial carcinoma. Immediately after collection, kidney tissue was processed into a single-cell suspension and sorted using a 4-color flow cytometry panel to isolate living, CD45+immune cells. To aid in the multi-omic characterization, surface markers and T and B cell repertoires were sequenced in 2 samples (1 AGN patient and the nephrectomy control). These samples were incubated with an oligo-antibody TotalSeq-C cocktail containing 130 unique cell surface antigens.

2024-06-28 | E-MTAB-13596 | biostudies-arrayexpress

Differential activity of treatment with protein kinase inhibitors on tumor phosphotyrosine profiles in patients with advanced cancer

Project description:Mass spectrometry-based phosphoproteomics of tumor tissue lysates provides a potential personalized medicine approach based on its ability to identify activated signaling pathways and novel drug targets. We performed a pilot study (NCT01636908) to determine the effect of protein kinase inhibitors (PKIs) on tyrosine-(pTyr)-phosphoproteomic profiles of serial tumor biopsies in patients with advanced cancer. Tumor needle biopsies were analyzed from 31 patients with advanced cancer before and after 2 weeks treatment with sorafenib (SOR), erlotinib (ERL), dasatinib (DAS), vemurafenib (VEM), sunitinib (SUN) or everolimus (EVE). pTyr-Phosphoproteomics of pre- and on-treatment biopsies was performed by phosphotyrosine immunoprecipitation followed by LC-MS/MS.

2019-04-18 | PXD008032 | Pride

Clonal structure and dynamics of human memory B cells and circulating plasmablasts

Project description:Using single cell sequencing of multi-year serial blood samples from two healthy donors we found that the memory B cell repertoire was dominated by large clonal families producing IgM, IgG2 and IgA, of which 0.2% share nearly identical VH/VL sequences in different individuals. In contrast, IgG1 families, including those encoding antibodies to T-dependent antigens, were of small size. Longitudinal samples collected over a period of several years showed the overall stability of the memory B cell pool in all its subsets. Surprisingly, clonotype stability was also found in serial samples of circulating plasma cells that largely overlapped with long-term memory B cells and contained recurrent clonotypes of IgA and IgG2 and, at lower frequency, IgG1 specific for recall antigens. Collectively, this study provides a global view of the structure, stability and dynamics of the human memory B cell pool and reveal that a large fraction of the clonal families is active at any time point in the generation of plasma cells involving both T independent and T dependent responses.

2022-04-20 | GSE188681 | GEO

Sammut2022 - Multi-omic machine learning model to predict pathological complete response for breast cancer neoadjuvant therapy

Project description:In this publication, researchers investigated the intricate relationship between breast cancers and their microenvironment, specifically focusing on predicting treatment responses using multi-omic machine learning model. They collected diverse data types including clinical, genomic, transcriptomic, and digital pathology profiles from pre-treatment biopsies of breast tumors. Leveraging this comprehensive multi-omic dataset, the team developed ensemble machine learning models using different algorithms (Logistic Regression, SVM and Random Forest). These predictive models identifies patients likely to achieve a pathological complete response (pCR) to therapy, showcasing their potential to enhance treatment selection. Please note that the authors also have an interactive dashboard to apply the fully-integrated NAT response model on new (or any desired) data. The user can find its link in their GitHub repository: https://github.com/micrisor/NAT-ML For more information and clarification, please refer to the ReadMe_NAT-ML document in the files section.

2023-08-28 | BIOMD0000001075 | BioModels

Circulating tumor extracellular vesicles to monitor metastatic prostate cancer genomic and transcriptomic evolution

Project description:Extracellular vesicles (EVs) secreted by tumors are abundant in plasma, but their potential for multi-omic profiling remains widely unexplored. Here, we pursued next-generation sequencing of circulating EV-DNA and EV-RNA in metastatic prostate cancer (mPC), using a range of in-vitro and in-vivo models, validating our findings in 35 mPC patients with longitudinal samples collected during androgen receptor signaling inhibitor (ARSI) therapy. EV-DNA copy-number (CN) profiles matched same-patient biopsies and ctDNA (p<0.001) and EV-DNA tumor fraction (TF) associated with shorter time to progression. We developed a novel approach for studying mRNA in circulating EVs (RExCuE), showing high correlation between EV-RNA and tumor biopsies (r>0.7, p<0.001). EV-RNAseq signatures at 4 weeks of therapy associated with clinical responses. Last, we derived a specific signature of ARSI response in EV-RNA in vivo that predicted response to therapy. In conclusion, EV profiling enables the study of mPC evolution at transcriptomics level in liquid biopsies.

2024-06-30 | GSE221709 | GEO

Multi-omics analysis of serial samples from metastatic TNBC patients on PARP inhibitor monotherapy provide insight into rational PARP inhibitor therapy combinations

Project description:In a pilot study, we evaluated the safety and efficacy of olaparib/durvalumab combination treatment in mTNBC patients and the feasibility of real-time deep analysis of serial tumor samples from triple negative breast cancer patients to identify mechanisms of resistance and treatment opportunities. This study used the SMMART analytic platform at OHSU KCI and incorporated comprehensive multi-omic analysis of serial liquid and tumor biopsies. Deep analysis of longitudinal biopsies combined with a robust computational biology pipeline identified multiple PARPi-induced changes in immune activation, DNA damage checkpoint activation, apoptosis and signaling pathways including RTK, PI3K-AKT and RAS-MAPK. These emergent tumor and immune state changes could act as biomarker targets to be used in selecting patient specific combination therapies.

| EGAS00001005479 | EGA

Analysis of epigenetic changes in survivors of preterm birth reveals the effect of gestational age and evidence for a long term legacy

Project description:Genome-wide DNA methylation profiling of DNA extracted from dried blood spots from preterm and term subjects using longitudinal samples collected at birth and 18 years of age. Infinium HM450 arrays were used to measure methylation at 347,789 autosomal CpGs. DNA was analysed from individuals at birth and 18-years and included 12 preterm and 12 term controls. Bisulphite converted DNA from the 48 samples were hybridised to the Illumina Infinium 450K Human Methylation Beadchip

2013-10-20 | E-GEOD-51180 | biostudies-arrayexpress

Temporal Expression Profiling of Plasma Proteins in Type 1 Diabetes Progression

Project description:A longitudinal proteomic profiling of human plasma using TMT-10plex-based LC-MS/MS analysis was performed to track temporal proteomic changes of T1D patients (n = 11) across 9 serial time points, spanning the period of T1D natural progression, in comparison with those of the matching healthy controls (n = 10). Longitudinal expression profiles of >2000 human plasma proteins in T1D natural progression were presented in the current study.

2018-03-08 | PXD007884 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data